Interim Report January–September 2019
Interim Report January–September 2019July – September in summary · Net sales rose by 164 percent to SEK 24,279 (9,206) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 7,987 (1,747) thousand. · Comprehensive income for the period improved by SEK 7,131 thousand to SEK 7,473 (342) thousand. · Comprehensive income per share, basic and diluted, improved by SEK 0.11 to SEK 0.12 (0.01). · Genovis delivered an order worth 13,5MSEK of SmartEnzymes[TM] for use in the manufacturing process for a biological drug. This is a new application for